This site is intended only for all Healthcare Professionals residing in South Africa




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information



Dosage Efficacy Indications Multimodal approach to post-operative pain Prescribing Information Safety and Tolerability Safety Information
  • The recommended dose is a single or initial 40 mg administered intravenously (IV) or intramuscularly (IM), followed every 6 to 12 hours by 20 mg or 40 mg as required, not to exceed 80 mg/day
  • The IV bolus injection may be given rapidly and directly into a vein or into an existing IV line
  • The IM injection should be given slowly and deeply into the muscle
  • When given at the recommended doses for management of acute pain, the onset of analgesia was 7-14 minutes and reached a peak effect within 2 hours
  • After a single dose, the duration of analgesia was dose and clinical pain model dependent and ranged from 7 to greater than 24 hours
  • Opioid analgesia can be used concurrently with RAYZON® (parecoxib sodium) dosing, for the management of post-operative pain for up to 48 hours
  • In a hip replacement surgery trial, the daily requirements for opioid were reduced by 20 to 40 % when co-administered with RAYZON® (parecoxib sodium)
  • An optimal effect is achieved when RAYZON® (parecoxib sodium) is given at the end of hip replacement surgery, prior to opioid administration
  • RAYZON® (parecoxib sodium) was administered at a fixed time interval (i.e. 12 hourly), whereas the opioids were administered when needed (PRN basis)
ReferencesRAYZON® Package Insert, approved 15 June 2021.
Support & Services

Copyright ©2024 Pfizer South Africa All rights reserved.

  • The information contained herein is provided for educational purposes only and is not intended to constitute medical advice or replace discussions with a Healthcare Professional. All decisions regarding patient care must be made with a Healthcare Professional, considering the unique characteristics of the patient.
  • While every effort is made to update the information regularly and to offer the most current, correct and clearly expressed information possible, Pfizer cannot be held responsible for any inaccuracy, errors, omissions or misinterpretations.
  • Pfizer, its officers and/or its employees do not accept or take any responsibility whatsoever for any loss, whether direct, indirect or consequential, which may arise from reliance on information contained on these pages and actions resulting therefrom. Any liability that would or could arise as a result of the contents of these pages is hereby excluded to the fullest extent allowed by law.
  • No warranty is given that any files, downloads or applications available via this web site are free of viruses which have the ability to corrupt your system.
  • Any and all information is subject to change without notice.
  • The information provided in this site is intended only for appropriate Healthcare Professionals residing in South Africa.


PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for all Healthcare Professionals residing in South Africa. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer South Africa 

Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).


Copyright © 2024. Pfizer Laboratories (Pty) Ltd. All rights reserved

For South Africa Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.

I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

Yes No
You are now leaving the PfizerPro South Africa website
You are leaving the South Africa HCP Portal website and being directed to a new website

This website is not controlled by South Africa HCP portal or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable
You are now leaving PfizerPro You are now leaving PfizerPro and will be directed to our provider to complete your registration. Any personal information that you may find prepopulated from your PfizerPro profile, or you may provide, will be governed by Privacy Policy. Your data will not be used for any other purpose.